目的 探討丁苯酞聯(lián)合前列地爾治療缺血性腦卒中的臨床療效及對超敏C反應(yīng)蛋白（hs-CRP）的影響。方法 收集2014年1月—2016年3月河南科技大學(xué)第一附屬醫(yī)院收治的85例缺血性腦卒中患者，隨機分為對照組（43例）和觀察組（42例）。兩組患者均接受常規(guī)治療，對照組在常規(guī)治療基礎(chǔ)上給予注射用前列地爾10 μg靜脈推注，1次/d。觀察組在對照組的基礎(chǔ)上加用丁苯酞膠囊0.2 g/次，3次/d，頓服。兩組患者均連續(xù)治療14 d。觀察比較兩組治療前后的神經(jīng)功能缺損評分（NIHSS）、日常生活自理能力量表（ADL）、hs-CRP、凝血功能指標(biāo)的變化，以及臨床療效。結(jié)果 治療14 d后，兩組的NIHSS、ADL評分、hs-CRP水平均有明顯改善，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）。觀察組的NIHSS評分顯著低于對照組，ADL評分明顯高于對照組，且hs-CRP水平明顯低于對照組，組間比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療前，兩組的凝血功能指標(biāo)比較差異無統(tǒng)計學(xué)意義。治療14 d后，兩組的凝血酶原時間（PT）、D-二聚體（DD）及纖維蛋白酶原（FIB）均較治療前有明顯改善，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組的PT顯著高于對照組，DD和FIB明顯低于對照組，組間比較差異有統(tǒng)計學(xué)意義（P<0.05）。此外，觀察組患者的臨床治療有效率（90.5%）顯著高于對照組（72.1%），差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 相較于前列地爾單一用藥，聯(lián)合丁苯酞治療能更好改善缺血性腦卒中患者的神經(jīng)功能、日常生活能力及凝血功能，抑制hs-CRP水平，臨床療效顯著。

Objective To investigate the clinical efficacy of alprostadil combined with butylphthalide on patients with acute ischemic stroke and its effect on hs-CRP.Methods Eighty-five patients with acute ischemic stroke admitted into our hospital were divided randomly into observation group (n= 42) and control group (n= 43). Patients in control group were treated with alprostadil, and those in observation group were treated with alprostadil combined with butylphthalide. The neurologic impairment score (NIHSS), ADL score, hs-CRP, coagulation function, and clinical efficacy in the two groups were observed and compared. Results After 14 days of treatment, the NIHSS and ADL score in both groups were improved, and NIHSS in observation group were much lower than control group, ADL were much higher, and hs-CRP were markedly lower than that of control (P<0.05). And the coagulation function indexes in both groups were obvious lowered, and DD and FIB in observation group were conspicuously lower than those in control group, and PT were much higher (P<0.05). In addition, observation group with effective rate of 90.5% were significantly higher than that of control group with 72.1% (P<0.05).Conclusion Compared with only alprostadil treatment, alprostadil combined with butylphthalide had a better capability of treating patients with acute ischemic stroke by improving coagulation function and neurologic function, and inhibiting levels of hs-CRP.